The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
T2T Validation - NOD2, 2025Inflammatory and Regulatory Functions of NOD2 in the Setting of Parkinson’s Disease
Study Rationale: NOD2 is a signaling protein which has been found to be more abundant and more active in brain tissues of patients with Parkinson’s disease. Certain changes in the sequence encoding...
-
Summer 2021 RFP: Expanding Biological Understanding of PD, 2025SUPPLEMENT: Urinary Biomarkers of Retromer Dysfunction in Parkinson’s Disease
Study Rationale: “Retromer” is a molecular machine that regulates the trafficking of many proteins within a cell. While a dysfunction of Retromer is now known to be central in triggering and driving...
-
T2T Validation - Endolysosomal Targets, 2025In Vivo Efficacy of a TRPML1 Activating Compound in Alpha-synuclein PD Pre-clinical Models
Study Rationale: Many genes harboring mutations that increase the risk for developing Parkinson’s disease (PD) are associated with the cell’s recycling center, the lysosome. Compounds activating the...
-
T2T Validation - Endolysosomal Targets, 2025Development of in Vivo Biomarkers for TRPML1 Target Engagement and Analysis of Therapeutics
Study Rationale: The appropriate regulation of proteins and lipids within neurons is critical for human health. Lysosomes are specialized structures within cells that are responsible for the removal...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025IND-enabling Studies of a Promising USP30 Inhibitor as Disease-modifying Therapy for Parkinson's Disease
Study Rationale: While the cause of Parkinson's disease (PD) remains unknown for most patients, strong evidence indicates that damaged mitochondria in neurons likely play a causal role. Mitochondria...
-
Research Grant, 2025Clinical Development of the PET Tracer Candidate MODAG-009 for quantitative Detection of Alpha-synuclein Pathology in Parkinson’s Disease
Study Rationale: In both Parkinson's disease and multiple system atrophy (MSA), the protein alpha-synuclein becomes altered, resulting in the accumulation of clumps of aggregated alpha-synuclein in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.